8-K: CERO Therapeutics Faces Nasdaq Delisting Threat, Implements Reverse Stock Split to Regain Compliance

CERO Therapeutics Holdings, Inc. received a Nasdaq delisting notice for failing to meet the minimum bid price requirement and subsequently executed a 1-for-20 reverse stock split to regain compliance.

Summary

• CERO Therapeutics Holdings, Inc. (CERO) received a letter from Nasdaq on June 11, 2025, notifying them of non-compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum $1.00 closing bid price for continued listing.
• The non-compliance was observed for the 30 consecutive business day period between April 25, 2025, and June 9, 2025, during which the common stock's closing bid price was below $1.00 per share.
• The Company is not eligible for the standard compliance period specified in Nasdaq Listing Rule 5810(c)(3)(A) because it has effected one or more reverse stock splits over the prior one-year or two-year period with a cumulative ratio of 250 shares or more to one.
• CERO intends to timely request a hearing before the Nasdaq Hearings Panel, which will allow its securities to remain listed and eligible for trading on the Nasdaq Capital Market at least pending the ultimate conclusion of any hearing process.
• Effective at 12:01 a.m. ET on June 13, 2025, the Company completed a reverse stock split at a ratio of 1 new share for every 20 shares of Common Stock outstanding.
• The Common Stock began trading on the Nasdaq Capital Market on a post-split basis at the open of trading on June 13, 2025, with a closing bid price of $7.31 per share, which is above the $1.00 minimum requirement.
• Despite the current post-split price, there is no assurance that the closing bid price will remain above $1.00 per share for a sustained period, nor that the Hearings Panel will grant the Company's appeal of the delisting determination, meaning continued listing is not guaranteed.

Sentiment

Score: 3

Explanation: The company is facing a significant challenge (delisting) and has taken a reactive measure (reverse split) which carries inherent risks and does not guarantee long-term stability. While the immediate price is above $1, the underlying issue of sustained compliance and the ineligibility for a standard grace period are negative. The forward-looking statements also highlight significant operational risks.

Positives

• The Company has taken immediate action by effecting a 1-for-20 reverse stock split to address the bid price deficiency.
• The closing bid price on June 13, 2025, post-split, was $7.31 per share, which is well above the $1.00 per share minimum requirement.
• The Company intends to request a hearing before the Nasdaq Hearings Panel, which will allow its securities to remain listed and eligible for trading during the appeal process.

Negatives

• The Company failed to meet Nasdaq's minimum $1.00 bid price requirement for 30 consecutive business days (April 25, 2025, through June 9, 2025).
• CERO is ineligible for the standard compliance period due to prior reverse stock splits with a cumulative ratio of 250 shares or more to one, indicating a history of share price challenges.
• There is no assurance that the post-split bid price will remain above $1.00 per share for a sustained period.
• There is no assurance that the Nasdaq Hearings Panel will grant the Company's appeal, meaning delisting remains a potential outcome.

Risks

• The closing bid price may not remain above the $1.00 per share minimum requirement for a sustained period of time.
• The Nasdaq Hearings Panel may not grant the Company's appeal of the delisting determination.
• The Company may ultimately not regain compliance and could be delisted from the Nasdaq Capital Market.
• Outcomes of the Company's planned clinical trials and studies may not be favorable.
• One or more of the Company's product candidate programs may not proceed as planned for technical, scientific, or commercial reasons.
• Uncertainty regarding the availability and timing of results from preclinical studies and clinical trials.
• Uncertainty about regulatory approval to conduct clinical trials or to market products.
• Uncertainties regarding intellectual property protection.

Future Outlook

The Company intends to request a hearing before the Nasdaq Hearings Panel to appeal the delisting determination. While a reverse stock split has temporarily brought the share price above the minimum, there is no assurance that the price will remain compliant or that the appeal will be successful, meaning continued listing on Nasdaq is not guaranteed. The Company also faces risks related to the outcomes of its clinical trials, product development, regulatory approvals, and intellectual property protection.

Management Comments

• "The Company intends to timely request a hearing before the Hearings Panel."
• "The Companys securities will then remain listed and eligible for trading on the Nasdaq Capital Market at least pending the ultimate conclusion of any hearing process."

Industry Context

This event highlights the ongoing challenges faced by smaller biotechnology or pharmaceutical companies, particularly those in clinical development stages, in maintaining compliance with stock exchange listing requirements. Such companies often experience significant stock price volatility due to clinical trial results, regulatory milestones, and funding needs. Reverse stock splits are a common tactic to avoid delisting, but their long-term effectiveness depends on underlying business performance and investor confidence.

Comparison to Industry Standards

• Many early-stage biotech companies struggle with maintaining Nasdaq's minimum bid price, especially if clinical trial progress is slow or negative, or if significant capital raises dilute shares.
• Reverse stock splits are a standard, albeit often temporary, measure employed by companies across various industries to regain compliance with exchange listing rules, particularly for bid price deficiencies. For example, other small-cap biotechs have resorted to reverse splits when facing similar delisting threats.
• The effectiveness of such a split in the long term is often tied to subsequent positive news, such as successful clinical trial data or strategic partnerships, which are common drivers for sustained price recovery in the biotech sector.

Stakeholder Impact

• Shareholders: Face uncertainty regarding the Company's continued listing on Nasdaq, potential for further stock price volatility, and dilution from previous reverse stock splits. The recent 1-for-20 reverse split significantly reduces the number of shares held.
• Employees: Potential impact on employee stock options/grants value and overall company stability perception.
• Investors: Need to monitor the outcome of the Nasdaq hearing and the sustained bid price performance.

Next Steps

• The Company intends to timely request a hearing before the Nasdaq Hearings Panel.
• The Company's securities will remain listed and eligible for trading on the Nasdaq Capital Market pending the ultimate conclusion of any hearing process.
• The Company needs to ensure the closing bid price remains above $1.00 per share for a sustained period.

Key Dates

Recommendation

Keywords

CERO Therapeutics, Nasdaq, Delisting, Reverse Stock Split, Bid Price Requirement, Nasdaq Listing Rule 5550(a)(2), Biotechnology, Pharmaceuticals, Clinical Trials, Corporate Governance